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DeterMinantS of non-PerSiStence to antioSteoPorotic DrugS by 
uSing aDMiniStrative DatabaSe
Orlando V.1, Guerriero F.1, Monetti V.M.1, Putignano D.1, Moretti A.2, Iolascon G.2, Menditto E.1
1CIRFF- Center of Pharmacoeconomics, Naples, Italy, 2Second University of Naples, Naples, Italy
Objectives: Osteoporosis treatment involves several therapeutic tools, includ-
ing long-term drug therapy. Subjects with chronic disorders are more likely to be 
non-adherent and/or non-persistent to treatment than those with other diseases. 
Adherence is the extent to which patients take medication as prescribed by their 
physicians, whereas persistence is the time from treatment initiation to discontinu-
ation. Lack of persistence is common among subjects using oral anti-osteoporotic 
drugs, and leads to increased risk of fragility fracture. The aim of our study is to 
analyze the rates and reasons for discontinuation of anti-osteoporotic drugs in the 
Campania Region. MethOds: The study was a retrospective cohort study. Patients, 
aged ≥ 40 years, were enrolled if at least one prescription for any antiosteoporotic 
drugs had been filled from July 1, 2009 through June 30, 2010. Data were retrieved 
from an administrative database of medications prescription in Campania region. 
Patients were followed from the index date until the antiosteoporotic therapy dis-
continuation or end of the observation period (June, 30, 2011). Results: A total of 
30,048 were incident users of anti-osteoporotic drugs: 1, 731 (5.8%) males and 28,317 
(94.2%) females. The mean age [SD] of the cohort was 69.0 [10.0] years. Weekly bis-
phosphonate (51.1%), was the most commonly prescribed drug. In the overall cohort 
study, persistence rates were 34, 8% after 6 months, 13, 4% at one year. A multivariate 
Cox proportional hazard analysis showed that daily regimen (HR 1,9) treatments 
remained at a higher risk of early discontinuation compared to weekly regimen 
therapies. Patients who started treatment with a co-prescription with calcium and 
vitamin D had a lower risk of early discontinuation (HR 0.7). cOnclusiOns: Our 
data showed that the persistence to osteoporosis therapy is significantly worse 
than reported in literature. A better osteoporosis management should include drugs 
with less frequent dosing, to obtain both an increase in rate of persistence and a 
reduction in side-effect.
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uSe of MeDication reMinDerS in PatientS With rheuMatoiD arthritiS
Bruera S.1, Lopez-Olivo M.A.2, Barbo A.2, Suarez-Almazor M.E.2
1Baylor College of Medicine, Houston, TX, USA, 2The University of Texas, MD Anderson Cancer 
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Objectives: In this study we determined the characteristics of patients with RA who 
used these aids, and the association of reminder use with adherence. MethOds: 
201 patients with RA were included in this prospective cohort study examining 
treatment adherence. At baseline patients were asked if they used any special 
reminders such as pill containers, calendars, or diaries. Patients completed two self-
reported adherence questionnaires: the Compliance Questionnaire Rheumatology 
and the Adult AIDS Clinical Trials Group adherence questionnaire. Disease activity 
measures included number of swollen joints, number of tender joints, disease activ-
ity score (DAS28), and patient global assessment. Functional status was evaluated 
with the modified Health Assessment Questionnaire (MHAQ). Results: Mean age 
of the patients was 51 years, 75% were female, 53% were Hispanic, 25% white, and 
21% African American. Sixty-eight (34%) patients reported using a reminder: 53 
(26%) used special pill containers, 12 (6%) used calendars, and 3 (1%) diaries. Factors 
associated with the use of reminders were older age (p= 0.004), being white vs. 
Hispanic or African American (p= 0.003), being male vs. female (p= 0.005). Working 
patients were less likely to report using reminders (p= 0.006). No association was 
observed between education levels and use of aids. Use of reminders was associ-
ated with domains of self-reported adherence: adherence while away from home 
(r= 0.16, p= 0.03), when busy (r= 0.16, p= 0.03), and when running out of pills (r= 0.15, 
p= 0.04). cOnclusiOns: Older patients, males, and whites were more likely to use 
these aids, more often pill containers. Our study shows that reminders can assist 
patients with RA in taking their medications, particularly in situations when they 
are most prone to forget including being away from home or busy. Use of reminders 
should be encouraged by providers as a low cost aid to enhance adherence.
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PatientS With PSoriatic arthritiS (PSa)
Lyu R.1, Ding Q.2, Govoni M.3, Fan T.1
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Objectives: The objective of this study was to describe persistence with subcu-
taneous biologic over 12 months for newly treated PsA patients and evaluate the 
impact of prior DMARD use. MethOds: This was a retrospective analysis using IMS 
Disease Analyzer-Germany, an electronic medical records database. Adult (≥ 18 years 
of age) PsA patients who initiated therapy with subcutaneous biologics between 
January 1, 2009 and June 30, 2012 were included in the analysis. The first subcutane-
ous biologic prescription date served as their index date. Continuous observation 
of at least 12 months pre- and post-index date was required. Patients who were 
prescribed any biologic during the pre-index period or diagnosed with rheumatoid 
arthritis, ankylosing spondylitis, crohn’s disease, or ulcerative colitis during the 
study period were excluded from the study population. A chi-square test was used 
to measure differences between patients with and without use of pre-index DMARD. 
A multivariate logistic regression was created to assess the impact of DMARD use 
on persistence, controlling for baseline characteristics. Results: A total of 197 
biologic-naïve PsA patients were selected. Of these, 89 were free of PsO. The mean 
(SD) age of the patients was 49 (11) years, with 50% being female. The majority of 
patients (61%) indexed on adalimumab, while the remainder indexed on etanercept 
(35%) and golimumab (4%). In the overall PsA population, the persistence rate with 
the index subcutaneous biologic was 54.3%, with similar results among those with 
and without DMARD use (53% vs 56%, respectively). Multivariate analysis did not 
identify any significant predictors for persistence, including DMARD use (OR: 1.05; 
A systematic review identified retrospective and prospective observational stud-
ies reporting 12-, 18-, or 24-month persistence with denosumab, an osteoporosis 
therapy approved in 2010. Searches covered the period January 2011─May 2014 and 
were conducted in the PubMed and EMBASE databases, and conference abstract 
supplements from ACR, AMCP, ASBMR, WCO-IOF-ESCEO, and ISPOR. To be eligible, 
studies needed to report at least one estimate of persistence with denosumab in 
patients with osteoporosis, have a clear definition of persistence, and be in English 
language. Using a random effects model, pooled estimates of denosumab per-
sistence were calculated for retrospective and prospective studies separately. A 
subgroup analysis was conducted based on geographical regions. Results: The 
search identified 338 unique citations in PubMed and EMBASE, and 200 confer-
ence abstracts. After applying the eligibility criteria, 11 studies were included in the 
final review and meta-analysis (7 retrospective; 4 prospective). All studies reported 
at least one estimate of 12-month persistence; 9 studies included females only. 
For retrospective studies, the pooled persistence estimates were 74.6% (95% CI: 
65.4-82.9) at 12 months, 67.6% (65.2-70.0) at 18 months, and 57.2% (51.8-62.5) at 24 
months. For prospective studies, the pooled estimate of 12-month persistence was 
89.0% (95% CI: 84.6-92.7). In the subgroup analysis, European studies had higher 
pooled 12-month persistence estimates compared with North American studies 
(retrospective: 78.6% vs. 68.9%; prospective: 91.5% vs. 85.3%). cOnclusiOns: To 
our knowledge, this is the first systematic review and meta-analysis of persistence 
with denosumab in patients with osteoporosis. We identified a growing body of 
evidence, both prospective and retrospective, suggesting persistence to denosumab 
is higher than previously reported for other OP therapies1.1. Kothawala P, et al. Mayo 
Clinic. 2007; 82 (12): 1493-501.
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Objectives: This study examined persistence over 12 months for RA patients who 
were newly treated with subcutaneous biologics, and assessed if there are differ-
ences between patients with and without prior DMARDs experience. MethOds: 
In this retrospective cohort study using Electronic Medical Record database of IMS 
Disease Analyzer-Germany, adult (≥ 18 years old) RA patients with exposure to a 
subcutaneous biologic between January 1, 2009 and June 30, 2012 were identified. 
The first prescription date for the subcutaneous biologic agent was defined as 
their index date. Patients were excluded from the study if they were prescribed 
a biologic agent during the pre-index period, and/or diagnosed with ankylosing 
spondilitis, psoriatic arthritis, or other conditions treated with subcutaneous bio-
logics either pre- or post-index. A chi-square test was used to assess significant 
differences in the percentage of persistent patients between those with and with-
out DMARD use and a logistic regression model was used to control for differences 
in baseline demographic and clinical characteristics. Results: A total of 576 RA 
patients without prior biologic experience met the study selection criteria; 471 
were DMARD experienced and 105 were DMARD naive. The mean (SD) age of the 
patients was 57 (13), with 75% being female. The majority of patients indexed 
on etanercept (46%) or adalimumab (40%). Forty eight percent of the patients 
persisted on their index biologic over the 12 months post-index period, with the 
rate significantly higher among those with pre-index DMARD use (51% vs. 31%; 
p= 0.0012). After controlling for pre-index characteristics, patients with pre-index 
DMARD had 2.23 times the odds of being persistent compared to those without 
pre-index DMARDs (OR: 2.23, 95% CI: 1.37-3.62). cOnclusiOns: Approximately 
half of biologic naïve RA patients were persistent over a 12-month period with 
their index subcutaneous biologic, with rates significantly higher among patients 
with pre-index DMARD.
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Objectives: This study aimed to describe persistence with subcutaneous biologics 
among biologic naïve AS patients over 12 months, and to identify differences among 
patients with and without NSAID drug experience. MethOds: This retrospective 
study used IMS Disease Analyzer-Germany, an electronic medical records database. 
Data for adult (≥ 18 years of age) AS patients with a prescription for subcutaneous 
biologic between January 1, 2009 and June 30, 2012 were used for this analysis. The 
index date was the date of the first subcutaneous biologic prescription. Prescription 
for any biologic during the pre-index period or diagnosis for rheumatoid arthritis, 
psoriatic arthritis or other conditions treated with subcutaneous biologics either 
in pre- or post-index qualified patients for exclusion from the study. Differences 
between pre-index NSAID naïve and experienced patients were measured using a 
chi-square test. A logistic regression model was used to further assess the impact 
of NSAID use on persistence, controlling for baseline characteristics. Results: The 
study cohort included a total of 108 biologic naïve AS patients, 72 with use of NSAIDs 
in the pre-index period. The mean age of the AS cohort was 42 years, with 70% of 
patients being male. Adalimumab, etanercept, and golimumab were initiated by 
61%, 28%, and 11% of patients, respectively. Persistence for at least 12 months with 
the index subcutaneous biologic was observed in 46.3% of the overall cohort, with 
similar results among those with and without NSAID use (47% vs 44%, respectively). 
Multivariate analysis confirmed similar persistence between those with and without 
pre-index NSAID (OR: 0.97; 95% CI: 0.39-2.44). cOnclusiOns: Findings from this 
German study showed that less than half of AS patients are persistent with the 
index subcutaneous biologic over a 12 month period. Results were similar irrespec-
tive of prior use of NSAIDs.
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infusion being least preferred (worst option in 45% of the cases). The second most 
relevant attribute was “necessity of combination therapy with methotrexate”, 
with DMARDs not requiring such combination being most preferred (in 43% of the 
cases). cOnclusiOns: Our data indicate that, of the included attributes, the most 
important ones are route of administration (oral being the number one choice by 
majority) and combination therapy with methotrexate (with DMARDs not requiring 
such combination being the most preferred) for RA patients’ choice. This research 
was funded by Pfizer GmbH.
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are PatientS’ PreferenceS tranSferable betWeen countrieS? a croSS-
euroPean DiScrete-choice exPeriMent to elicit PatientS’ PreferenceS 
for oSteoPoroSiS Drug treatMent
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University of Aberdeen, Aberdeen, UK, 5Ghent University Hospital, Ghent, Belgium, 6University 
of Liège, Liège, Belgium, 7Paris Descartes University, Paris, France, 8Our Lady’s Hospital, 
Manorhamilton, Ireland, 9Hospital del Mar-IMIM and RETICEF, Barcelona, Spain, 10Geneva 
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Objectives: Discrete-choice experiments are increasingly used to assess pref-
erences in health care. To date, very little is known about the transferability of 
patients’ preferences between jurisdictions. In this study, we aim to evaluate the 
preferences of patients with, or at risk of, osteoporosis for medication attributes 
in six European countries, and to assess whether preferences are transferable 
across these countries MethOds: A discrete-choice experiment was conducted 
using a questionnaire in Belgium, France, Ireland, Spain, Switzerland and United 
Kingdom. Patients were asked to choose between two hypothetical unlabelled 
drug treatments (and an opt-out option) that vary in several attributes: efficacy 
in reducing the risk of fracture, type of potential common side-effects, mode 
and frequency of administration and out-of-pocket costs (only in countries with 
patients´ contribution on the cost of treatment). An efficient design was used to 
construct the treatment option choice sets and a mixed logit model was used to 
estimate patients’ preferences. Results: A total of 1,124 patients completed the 
experiment, with at least 100 patients per country. As expected, in all countries, 
patients preferred treatment with higher effectiveness and lower cost was pre-
ferred in the three countries in which a cost-attribute was part of the experiment. 
In all countries, patients preferred 6-monthly subcutaneous injection over weekly 
oral tablets. In most countries, patients also preferred monthly oral tablet and 
yearly intravenous injections over weekly oral tablets. Patients disliked being at 
risk of gastro-intestinal disorders more than being at risk of skin reactions and 
flu-like symptoms, except in Spain. There were significant differences between 
countries for some levels of attributes. cOnclusiOns: This study suggests that 
the preferences of patients for osteoporotic drug therapy did not substantially 
differ between six European countries. However, for levels of some attributes, 
significant differences were observed.
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long-terM Maintenance of iMProveMentS in Patient-rePorteD 
outcoMeS With certolizuMab Pegol in PatientS With axial 
SPonDyloarthritiS, incluDing ankyloSing SPonDylitiS anD non-
raDiograPhic axial SPonDyloarthritiS: 96-Week reSultS of the 
raPiD-axSPa StuDy
Sieper J.1, Kivitz A.2, van Tubergen A.3, Deodhar A.4, Szegvari B.5, Nurminen T.6, Landewé R.7
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Objectives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA), 
including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), 
over 96 weeks (wks) of the RAPID-axSpA trial. MethOds: The RAPID-axSpA trial 
(NCT01087762) is double-blind and placebo-controlled to Wk24, dose-blind to 
Wk48, and open-label to Wk204. Patients fulfilled ASAS criteria and had active 
axSpA. Patients originally randomized to CZP (200mg Q2W or 400mg Q4W, fol-
lowing 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in 
the dose-blind phase and OLE. Here we report PRO data for the CZP-treated rand-
omized set, including mean change from baseline and the proportion of patients 
achieving a Minimal Clinically Important Difference (MCID). Missing data were 
imputed by LOCF. Correlations between clinical and patient-reported outcomes 
were also investigated. Results: Of 218 patients randomized to CZP, 203 (93%) 
completed Wk24, 191 (88%) Wk48, and 174 (80%) Wk96. Rapid improvements from 
baseline to Wk24 were maintained to Wk96 in all patient subpopulations (overall 
axSpA, AS, nr-axSpA) in pain (Wk24: -3.2, -3.2, -3.3; Wk96: -3.6, -3.6, -3.7); fatigue 
(Wk24: -2.7, -2.5, -2.9; Wk96: -2.9, -2.8, -3.1); BASFI (Wk24: -2.4, -2.3, -2.4; Wk96: 
-2.6, -2.6, -2.6); ASQoL (Wk24: -5.1, -4.8, -5.5; Wk96: -5.7, -5.5, -6.1) and sleep (Wk24: 
-12.8, -10.5, -15.7; Wk96: -13.9, -11.6, -16.7). CZP-treated patients also maintained 
improvements in SF-36 components and domains. Sustained improvements in 
the proportion of patients (overall axSpA, AS, nr-axSpA) achieving MCID (%) were 
observed in fatigue (Wk24: 78.4, 76.0, 81.4; Wk96: 67.0, 70.2, 62.9); BASFI (Wk24: 
67.4, 68.6, 66.0; Wk96: 64.2, 68.6, 58.8) and ASQoL (Wk24: 69.3, 71.1, 67.0; Wk96: 65.6, 
66.9, 63.9). Similar outcomes were seen with both dosing regimens. Correlations 
were observed between improvements in PROs (pain/fatigue/SF-36) and clinical 
outcomes (ASDAS) (data not shown). cOnclusiOns: Improvements in PROs 
(including pain, fatigue and ASQoL) were maintained over 96 wks in both the 
AS and nr-axSpA subpopulations. Sustained improvements in the proportion of 
patients achieving MCID were also reported.
95% CI: 0.53-2.07) and psoriasis (OR: 1.07; 95% CI: 0.56-2.03). cOnclusiOns: More 
than half of the PsA patients were persistent with the index subcutaneous biologic 
over a 12-month period with similar persistence rates observed among those with 
and without psoriasis and DMARD use.
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iMPact of MeDication aDherence by uSing inDian verSion coMPliance 
QueStionnaire rheuMatology (cQr) anD MeDication aDherence 
rePort Scale (MarS) toolS on Quality of life of PatientS With 
rheuMatoiD arthritiS
Shetty R.1, Reddy K.2, Inam S.2, Khera K.1
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Objectives: To assess medication adherence to DMARD in patients with 
Rheumatoid Arthritis using CQR and MARS tools, identification of factors affecting 
adherence and its effect on quality of life. MethOds: A randomly selected sample 
of 110 adult patients with RA on DMARDs admitted to hospital were asked about 
their medication adherence, through self-report questionnaire [CQR and MARS] and 
quality of life was assessed by HAQ (Health Assessment Questionnaire). Additionally, 
various factors affecting adherence were identified. Results: According to the tools 
used, 86.4% (CQR), 74.29% (MARS -mean cut point) and 95.45% (MARS -prior study 
cut point) of patients showed adherence towards DMARD. Better adherence was 
seen in patients with primary education (COR- 94%) or secondary education (MARS 
-83%). Patients who suffered from RA for more than 2yrs showed better adherence 
(CQR- 93%) compared to those with recent disease (< 2yrs) (CQR- 89%). Non adher-
ence was seen in patients having co-morbidities compared to patients with only RA 
(CQR- 91% vs 94%; MARS- 62% vs 82%). Mean HAQ of adherent patients was better 
(2.83±1.05) than non-adherent patients (3.23 ± 0.74). Adherent patients showed mod-
erately active disease state (Mean DAS – 5.96 ± 1.67) whereas, non-adherent patients 
showed highly active disease state (Mean DAS – 6.70 ± 0.84). cOnclusiOns: Patient 
reported questionnaires showed disease duration of less of 2yrs, and patients with 
co-morbidities lead to Non-adherence which worsened disease activity which lead 
to decreased quality of life.
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Quality of life in PSoriatic arthritiS: conSiStent anD Stable  
acroSS DataSetS
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Objectives: Psoriatic arthritis (PsA) is a multi-factorial disease that affects the skin, 
joints and soft tissues. Two of the commonly used measures for PsA are the Psoriasis 
Area and Severity Index (PASI, 0-100 scale) and the Health Assessment Questionnaire 
(HAQ, 0-3 scale) for skin and joints symptoms, respectively. Previous work in the 
area has estimated a relationship between these patient-reported instruments and 
utility (SF-36 mapped to the EQ-5D). The objectives of this study were to calculate 
patient-reported utility and investigate the consistency of the relationship between 
PASI, HAQ and utility with previously published estimates, based on the PSUMMIT 
trials of ustekinumab versus placebo. MethOds: Patient level data from PSUMMIT1 
(anti-TNFα naïve) and PSUMMIT2 (both anti-TNFα naïve and experienced) were 
analysed in Stata 11. SF-36 data were converted to EQ-5D using the mapping by 
Rowen et al., with regression analysis used to estimate the relationship between 
PASI, HAQ and the resulting utility (including multiplicative terms). Goodness of fit 
was determined by the adjusted R2 and Root Mean Squared Error (RMSE). Results: 
Anti-TNFα naïve and experienced patients had a baseline utility of 0.50 and 0.48, 
respectively. Utility improved over the 24-week blinded period by 0.04/0.06 in the 
placebo arms for anti-TNFα naïve and experienced, and 0.11/0.13 in the treatment 
arms. In regression analysis utility was predicted as 0.897 – 0.004xPASI - 0.298xHAQ 
(adjusted R2 0.60, RMSE 0.12), similar to previously published estimates. Adding a 
multiplicative term for PASI and HAQ did not improve goodness of fit statistics, 
although baseline methotrexate use was linked to a lower utility. cOnclusiOns: 
Patients with PsA have a low level of health-related quality of life that improves with 
treatment. The determinants of utility in the PSUMMIT trials were the skin and joint 
symptoms faced by patients, in keeping with previous estimates.
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Objectives: There is a variety of biologic and non-biologic disease modifying anti-
rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). 
These DMARDs are associated with different characteristics in key attributes such as 
mode of administration, side effects, etc. The current study assessed the importance 
of treatment characteristics for RA patients’ preferences. MethOds: In a discrete 
choice experiment (DCE), 1570 RA patients are asked to choose the most and the 
least preferred DMARD (best-worst-scaling) among hypothetical multi-attribute 
treatment alternatives with varying levels of key attributes, as defined in focus 
groups: mode of administration, frequency of administration, time till onset of 
drug effect, necessity of combination therapy with methotrexate, and side effects. 
The multi-profile case design simulates a real choice situation between different 
hypothetical treatment alternatives. Interim analysis was conducted after half the 
sample size had been reached. Results: Interim analysis included 836 patients 
from 33 office based rheumatologists across Germany. Majority of patients were 
female (74%), 50 to 64 years of age (46%), with < 10 years of disease duration (54%), 
and reported experience with injectable DMARDs (63%). Mode of administration 
appeared the most important attribute guiding patients’ preferences, with ‘oral 
application’ being most desired (selected as best option in 51% of the cases) and 
